The latest announcement is out from Abbisko Cayman Limited ( (HK:2256) ).
Abbisko Cayman Limited has announced the composition of its board of directors and their roles within the company. The board includes executive directors Dr. Xu Yao-Chang, Dr. Yu Hongping, and Dr. Chen Zhui, along with independent non-executive directors Dr. Sun Piaoyang, Mr. Sun Hongbin, and Ms. Chui Hoi Yam. The board has established three committees: Audit, Remuneration, and Nomination, with specific members assigned to each. This announcement highlights the company’s governance structure, which is crucial for its strategic decision-making and operational oversight.
More about Abbisko Cayman Limited
Abbisko Cayman Limited is a company incorporated in the Cayman Islands, operating with limited liability. It is listed under the stock code 2256. The company is involved in the pharmaceutical industry, focusing on innovative drug discovery and development.
YTD Price Performance: 41.09%
Average Trading Volume: 2,805,575
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$4.41B
See more insights into 2256 stock on TipRanks’ Stock Analysis page.